46.48
+0.21(+0.45%)
Currency In USD
| Previous Close | 46.27 |
| Open | 46.26 |
| Day High | 46.49 |
| Day Low | 46.25 |
| 52-Week High | 62 |
| 52-Week Low | 28.21 |
| Volume | 5.87M |
| Average Volume | 4.96M |
| Market Cap | 3.5B |
| PE | -13.63 |
| EPS | -3.41 |
| Moving Average 50 Days | 44.42 |
| Moving Average 200 Days | 40.17 |
| Change | 0.21 |
If you invested $1000 in SpringWorks Therapeutics, Inc. (SWTX) since IPO date, it would be worth $2,053.91 as of May 25, 2025 at a share price of $46.48. Whereas If you bought $1000 worth of SpringWorks Therapeutics, Inc. (SWTX) shares 5 years ago, it would be worth $1,189.05 as of May 25, 2025 at a share price of $46.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire Inc.
May 23, 2025 12:00 PM GMT
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European Commission expected in the third quarter of 2025 – STAMFOR
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
GlobeNewswire Inc.
Apr 28, 2025 6:13 AM GMT
– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
GlobeNewswire Inc.
Apr 27, 2025 2:35 PM GMT
STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee f